This website is intended for use by adults only. The content and all information provided herein is for your informational use only and is not intended to be a substitute for professional medical advice, diagnosis or treatment in any manner. The statements quoted on this website reflect the views and opinions of the patient; Medtronic has not verified any claims and makes no representation as to the accuracy or reliability of the information provided. Statements have been provided by patients of their own free will and Medtronic has had no editorial input into the substance or form of these statements. The patient stories provided are experiences specific to a particular patient. Responses to a treatment may vary from patient to patient. Always talk with your physician about diagnosis and treatment information and ensure that you understand and carefully follow that information.
All links to the social media sites are provided as a service to you, and such linkage does not constitute endorsement of those sites by Medtronic, and as such we are not responsible for the content of external web sites of any comments or responses posted to any web site or social media site by you or anyone else. By submitting any content to any of the social media sites, you understand and acknowledge that this information is available to the public, and that Medtronic may use this information for internal and external promotional purposes. Medtronic shall make reasonable efforts to monitor the content posted on the social media platforms and Medtronic reserves the right to review, edit and/or delete any comments it deems to be inappropriate (e.g. offensive comments, spam).
© 2013 Medtronic of Canada, Ltd. All Rights Reserved. No part of this website may be reproduced or utilized in any form or by any means without permission from Medtronic International Trading Sarl.
Veo, Bolus Wizard, and MiniLink are trademarks and MiniMed and Medtronic CareLink are a registered trademark of Medtronic MiniMed, Inc.
*The CGM System requires the use of the MiniLink™ transmitter and glucose sensors (sold separately).
**Based on the 2008 Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada
1. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320
2. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
*Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2055;25:1245-1249.
4. Minkina-Pedras M, Jarosz-Chobot P, Polanska J, Kalina MA, Marcinkowski A, Malecka-Tendera E. Prospective assessment of continuous subcutaneous insulin infusion therapy in young children with type 1 diabetes Diabetes Res Clin Pract. 2009 Aug;85(2):153-8. Epub 2009 Jun 18.
5. Müller-Godeffroy E, Treichel S, Wagner VM. Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus--a large-scale multicentre pilot study Diabet Med. 2009 May;26(5):493-501.
6. Danne T, Battelino T, et. al. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia. 2008 Sep;51(9):1594-601. Epub 2008 Jul 1.
7. Misso ML et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus (Review).The Cochrane Collaboration. The Cochrane Library 2010, Issue 1
8. Karagianni P et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Hippokratia 2009;13(2):93-96
9 The EQuality1 Study Group. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabetic Medicine 2008;25(2):213-220